Autolus Therapeutics delivered a quarter that looks better on the income statement than on the trajectory chart. The company reported a third-quarter loss of $0.21 per share. That matched the consensus estimate and beat the Earnings Whisper number of -$0.24 by 12.5%. AUCATZYL net product revenue of $41.24 million topped the $38.75 million consensus by 6.4% and grew 94.6% year over year. Earnings improved 30.0% from the prior-year loss of $0.30 per share. Management also tightened full-year 2026 AUCATZYL guidance to at or above the upper end of $150 million. That marks the third consecutive upgrade, after the outlook began the year at $120-135 million. The central tension is that revenue fell sequentially from $45.7 million in the second quarter. The new outlook implies a fourth quarter of roughly $37 million or more, so the launch curve has flattened even as the annual number keeps rising.
The margin story is the strongest part of the release. Gross margin reached 57%, up from 55% in the second quarter and from a negative margin a year earlier. That is a remarkable swing from roughly 6% as recently as the first quarter. Cost of sales fell to $17.9 million from $28.6 million on lower manufacturing cost per batch, higher volumes and smaller inventory write-offs. Loss from operations narrowed to $43.5 million from $71.6 million a year ago. The quality of the bottom line deserves scrutiny, however. Net loss widened sequentially to $55.1 million from $39.1 million. Other expense of $12.0 million, tied in part to the Perceptive debt now on the balance sheet, absorbed much of the operating progress. R&D also rose to $30.9 million. Year over year, Q3 revenue growth of 95% trails the 122% pace for the first nine months, which is a clear deceleration.
On the call, management framed the soft quarter as a pattern rather than a problem. Executives likened it to 2025's flat second-through-fourth-quarter shape and cited holiday seasonality as a fourth-quarter headwind. They also acknowledged that growth increments in years three and four will be smaller than the year-one-to-two step-up. The footprint argues against a demand stall. U.S. activated centers rose to 90 from 82 last quarter, beating the 80-center target, and the U.K. reached 18. Management attributed growth mainly to deeper use within existing centers, as physicians gain experience and the ROCCA real-world data circulates. Still, more centers producing lower quarterly revenue is a question analysts pressed on. The company did not offer a firm answer on when sequential growth resumes.
The pipeline produced both catalysts and a notable setback. FDA granted RMAT designation to obe-cel in lupus and lupus nephritis. CARLYSLE data with up to 25 months of follow-up will be presented at ACR. ASH in December brings first AUTO8 data in light-chain amyloidosis plus additional ALL data. The setback is that the first BOBCAT progressive-MS readout slipped from early 2027 to ECTRIMS in October 2027. Management cited KOL advice favoring at least 12 months of follow-up and said the study itself is not delayed. Enrollment expanded to 24 patients to test two lymphodepletion regimens. The timeline for peak 65-70% gross margins also drifted to 2028, from the 12-18 months framed last quarter. Safety questions around CAR-T in autoimmune disease remain an overhang.
The balance sheet bought time but changed character. Cash rose to $248.4 million after the $75 million Perceptive tranche, and the runway remains into the second quarter of 2028. Shareholders' equity, however, has shrunk to $27.4 million from $178.1 million at year-end. That leaves limited cushion if commercial growth stays flat.
The market had already priced in considerable disappointment. Shares closed at $1.32 before the report, down 35.3% from the $2.04 open after the August release. They have fallen 48.8% from the 52-week high of $2.58 set on August 19. The stock sits 20.6% below its 200-day moving average and just 7.8% above its inter-earnings low of $1.23 from November 5. Investor sentiment moved the other way, rising meaningfully from 0.11 to 0.35. Expectations warmed even as the price slid toward the bottom of its range.
The bottom line is that Autolus is executing well on what it controls: margins, center activation and full-year guidance. Bears still have legitimate ammunition in the sequential revenue decline, a widening net loss, debt-financed runway and a pushed-out MS catalyst. Improved sentiment and a depressed share price set a low bar. Sustained upside, however, likely requires evidence that AUCATZYL quarterly sales can grow again after a seasonally soft fourth quarter.